Group items tagged

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

(RFA-NS-19-025 is being reissued to accommodate an additional receipt date). The purpose of this funding opportunity announcement (FOA) is to invite applications for the Specialized Clinical Centers (hubs) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIHs Helping to End Addiction Long-term (HEAL) Initiative. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers (hubs). The purpose of this funding opportunity announcement (FOA) is to invite applications for the hubs within EPPIC-Net. A hub will typically be a regional medical center that will actively enroll subjects into clinical trials and studies performed in EPPIC-Net. Each hub should have ready access to patient populations with specific pain conditions and have expertise in characterization of that pain condition. A hub will additionally provide scientific leadership and administrative oversight to its multiple (2-10) satellite sites (spokes). This FOA solicits applications EPPIC-Net Specialized Clinical Centers. Separate FOAs have been issued to solicit applications for the Clinical Coordinating Center (RFA-NS-18-036) and Data Coordinating Center (RFA-NS-18-035). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL Partnership, as described above, or from separate NIH funding announcements.

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support two types of cancer centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas. The purpose of both types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious programs in laboratory, clinical, and population research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of shared resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

The purpose of this Funding Opportunity Announcement is to invite U54 cooperative agreement applications for Cooperative Centers of Excellence in Hematology (CCEH). The NIDDK Hematology Centers Program is designed to increase access to critical research resources and collaboration in the national multidisciplinary research effort to combat nonmalignant hematologic diseases and to study normal hematopoiesis. In addition, it aims to improve cost-effectiveness of preparing critical reagents, maintaining state-of-the-art resources, and running multi-step molecular biologic assays. Each CCEH will support a minimum of three Biomedical Research Cores, an Administrative Core, and an Enrichment Program. The CCEH are expected to work collaboratively with the NIDDK Hematology Central Coordinating Center -- together comprising the NIDDK Hematology Centers Program. By providing state-of-the-art equipment, resources, and expertise to the greater nonmalignant hematology research community, the program will serve as a national hub for nonmalignant hematology research, supporting career development of scientists just beginning their careers in the field and attracting established investigators from other domains. Funded Centers will cooperate with the NIDDK to facilitate research collaborations and interactions within and among Centers and with the wider research community.

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism. Each proposed U54 Partnership Center must be based on a collaboration between a research institution in the United States (as the applicant institution) and partnering institution(s) in low- and middle-income countries (LMICs) in the LAC region. The proposed clinical trials should be focused on optimizing clinical prevention interventions among HIV-infected individuals, including immunoprevention (vaccination), screening and triage, and precancer treatment. Each Partnership Center application must propose a Clinical Trials Program that will develop and conduct three prevention clinical trials within the 5-year project period. As infrastructure supporting the Clinical Trials Program, each Partnership Center should include an Administrative and Coordinating Core, a Data Management and Statistical Core, and a Central Laboratory Core. Results of the clinical trials conducted through the Partnership Centers are expected to influence the development of clinical practice guidelines to improve preventive clinical care and reduce the burden of highly preventable HPV-related cancers in HIV-infected individuals.

The National Cancer Institute (NCI), through its Center for Global Health (CGH), seeks to promote cancer prevention and control (CPC) research in low- and middle-income countries (LMICs) through collaborations and research partnerships between the NCI-designated cancer centers and partner institutions in LMICs. Through this funding opportunity announcement (FOA), the NCI will provide administrative supplement awards to currently-funded P30 NCI-designated cancer center grantees to support pilot research plans that focus on cancer prevention and control. These supplements are designed to stimulate and strengthen CPC twinning programs between researchers at the NCI-designated cancer centers and institutions in LMICs. It is anticipated that outcomes of this supplement will include collaborative research grants between investigators at the NCI-designated cancer centers and LMIC institutions.

The purpose of this FOA is to promote the creation of developing research centers that can build capacity to study high priority areas of cancer control implementation science, build implementation laboratories, improve the state of measurement and methods, and improve the adoption, implementation, and sustainment of evidence-based cancer control interventions. Specifically, this FOA targets the following areas designated as scientific priorities by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches; Symptom Management, Prevention and Screening: High-Risk Cancers and other cross-cutting Moonshot priorities. The Implementation Science Centers in Cancer Control (ISCCC) Program will support the rapid development, testing and refinement of innovative approaches to implementing a range of evidence-based cancer control interventions, establish implementation laboratories from existing clinical and community sites providing services across the cancer control continuum, advance methods in studying implementation, develop and validate reliable measures of key implementation science constructs, and together form a large consortium of implementation scientists across this and other Moonshot initiatives. The ISCCC Program will support P50 Developing Centers (under this FOA) and P50 Advanced Centers (companion RFA-CA-19-006).

The overarching goal of the Breast Cancer and the Environment Research Program (BCERP) is to support integrated scientific research to enhance our understanding of environmental and genetic factors underlying breast cancer risk. This funding opportunity will support a Coordinating Center, which together with a group of individual transdisciplinary projects investigating the influence of environmental exposures during specific time windows on breast cancer risk, will form the BCERP Consortium. The BCERP Coordinating Center will provide intellectual leadership as well as logistic support for the BCERP Consortium. A primary role of the BCERP Coordinating Center will be to identify opportunities for cross-BCERP collaborations and extend the transdisciplinary activities of the BCERP Consortium. The Coordinating Center will also assist in disseminating BCERP research findings and facilitating an internal evaluation of the Consortium.

This Funding Opportunity Announcement (FOA) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Coordination and Data Management Center (CDMC) are being solicited via RFA-DK-19-504 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CDMC) (U01 Clinical Trial Optional)". To effectively contribute to the ongoing CPDPC clinical studies, each CC applicant should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the CPDPC (see https://cpdpc.mdanderson.org/clinicalstudies.html). Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs.

The Virtual Cancer Center Director Award (VCCDA) mechanism is a unique, interactive virtual cancer center (VCC) focused on bringing together two established investigators (Director and Deputy Director) and up to nine early career investigators (Scholars) to interrogate the commonalities of cancer. Candidates for Scholars will apply to a separate funding opportunity (W81XWH-20-PRCRP-CDA). The Director and Deputy Director will catalyze the growth and professional development of the Scholars in collaboration with the Scholars' Career Guides, assess the progress of the Scholars, promote the cross pollination of different cancer disciplines, and facilitate communication and collaboration amongst all of the VCC members. The overarching goal of the VCC is to develop successful, highly productive Scholars in a collaborative research and career developmental environment. The VCC will provide intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The VCC will give Scholars opportunities to operate in a collegial, highly dynamic, and cutting edge center to lead cancer research to a new frontier. It is the intention that through the VCC, collaborations will foster new growth in different cancers and spur an integrated cancer center to ensure the research advancements across different cancers.

The Center to Reduce Cancer Health Disparities (CRCHD) of the National Cancer Institute (NCI), in partnership with the NCI Office of Cancer Centers (OCC), announces this opportunity to compete for administrative supplements to Cancer Center Support Grants (CCSGs; P30s) for NCI-designated Cancer Centers (CCs) to each recruit a Community Health Educator (CHE). The purpose of this administrative supplement funding opportunity is to support a strengthening of community outreach capacity by working through the National Outreach Network (NON). It is expected that NON CHEs, located at NCI-designated CCs, will enhance the development and dissemination of culturally appropriate, evidence-based cancer information to members of underserved communities including rural and racial/ethnic populations (e.g., African American/Black, American Indian/Alaska Native, Asian, Hispanic/Latino, Native Hawaiian/Other Pacific Islander) in a way that is tailored to their specific needs.

The purpose of this FOA is to promote the development of advanced research centers that can build capacity to study high priority areas of cancer control implementation science, build implementation laboratories, improve the state of measurement and methods, and improve the adoption, implementation, and sustainment of evidence-based cancer control interventions. Specifically, this FOA targets the following areas designated as scientific priorities by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches; Symptom Management, Prevention and Screening: High-Risk Cancers and other cross-cutting Moonshot priorities. The Implementation Science Centers in Cancer Control (ISCCC) Program will support the rapid development, testing, and refinement of innovative approaches to implementing a range of evidence-based cancer control interventions, establish implementation laboratories from existing clinical and community sites providing services across the cancer control continuum, advance methods in studying implementation, develop and validate reliable measures of key implementation science constructs, and together form a large consortium of implementation scientists across this and other Moonshot initiatives. The ISCCC Program will support P50 Advanced Centers (under this FOA) and P50 Developing Centers (companion RFA-CA-19-005).

· Virtual Cancer Center Scholar Option: Supports independent, highly accomplished early career investigators (referred to as Scholars) to conduct impactful research under the guidance of an experienced cancer researcher (i.e. Career Guide). Presents an opportunity for Scholars to participate in the unique, interactive Virtual Cancer Center (VCC) focused on fostering the next generation of cancer researchers. This award provides intensive mentoring, national networking, and a peer group for junior faculty. Scholars are required to interact with the VCC Director, Deputy Director, and fellow Scholars in addition to their Career Guide. For more information on the Virtual Cancer Center refer to the FY20 Virtual Cancer Center Funding Opportunity.

This Funding Opportunity Announcement (FOA) is a part of the Pediatric Preclinical Testing Consortium (PPTC) initiative. The PPTC will consist of in vivo and in vitro testing Research Programs (both supported under companion RFA-CA-14-018) and the PPTC Coordinating Center (supported under this FOA). The PPTC is designed to address key challenges associated with the development of new therapies for children with cancer by developing reliable preclinical testing data for pediatric drug candidates that can be used to inform new agent prioritization decisions. Effective prioritization is critical because of the large universe of drugs being developed for adult cancers, a number so large that no more than a small number can be studied in pediatric clinical trials. Identifying through preclinical testing those investigational agents most likely to have clinical activity for selected childhood cancers accelerates the pace at which treatments that are more effective than the current ones can be identified and incorporated into standard practice for children with cancer. The PPTC Research Programs, responsible for conducting the in vivo and in vitro testing of selected agents, will be focused on specific tumor types that are particularly relevant to pediatric oncology. The PPTC Coordinating Center, which is subject of this FOA, will be responsible for integrating the activities of the individual PPTC Research Programs to create a functional consortium for pediatric preclinical testing. Specifically, the PPTP-Coordinating Center will provide administrative coordination and infrastructure, data management and statistical support, as well as Consortium scientific coordination.

Founded in 1996, the Marsha Rivkin Center for Ovarian Cancer Research provides funding for multiple efforts, including funding for innovative research pilot studies, scholar grants to up-and-coming investigators to encourage their careers in ovarian cancer research, public early detection screening for ovarian cancer, and nationally and internationally attended research symposia focused on ovarian cancer. To advance this mission, the center has issued a Call for Applications for its 2018 Scientific Scholar Awards. Through the program, the center will award grants of up $120,000 over two years to promising laboratory and clinical scientists interested in pursuing a career as an independent investigator in ovarian cancer research. Funds are for direct costs only; institutional overhead and indirect costs are not covered by the award. Eligible applicants must have an MD, PhD, or equivalent degree with career goals focused on ovarian cancer, and clinicians must have completed their residency. All applicants should be at the postdoc/fellow, instructor, research assistant, or assistant professor level, with no more than three to four years in any of these positions. Established outstanding scientists without prior focus in ovarian cancer but looking to focus in this area are also encouraged to apply.

This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center. The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.

This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center. The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.

Founded in 1996, the Marsha Rivkin Center for Ovarian Cancer Research supports public early detection screening for ovarian cancer, produces nationally and internationally attended research symposia, and provides funding for innovative ovarian cancer research and scholar grants to up-and-coming investigators. The center is accepting applications for pilot study projects in ovarian cancer research. Through the center's Pilot Study Program, approximately ten one-year grants of $75,000 will be awarded to support investigator-initiated projects in all areas of ovarian cancer research. Projects designed to analyze data from already funded clinical trials also will be considered. Priority will be given to proposals that are innovative, multi-disciplinary, and likely to lead to the submission of grant applications for independently funded investigations. Investigators at all levels are encouraged to apply.

Through the program, grants of up to $60,000 will be awarded to community-based programs and/or healthcare agencies (e.g., community health centers, cancer centers, and women's health centers) that conduct outreach, provide breast health education, and help steer medically underserved women and men to breast cancer screening services and follow-up care, as needed. Programs should educate women in their communities about breast health and encourage women to talk with a doctor or nurse to understand their individual risk of breast cancer and at what age and how often they should be screened. In addition, applicants must incorporate into their programs systems to promote the re-screening of the women served by the program. Small, community-based organizations are encouraged to apply.

The purpose of the FOA is to support the development of collaborative, multi-disciplinary basic research centers to elucidate and integrate a mechanistic understanding of the non-linear, dynamic, and emergent processes in metastasis. It is anticipated that each center will use systems-level approaches that encompass chronological progression and biological scales to derive a more comprehensive and cohesive picture of metastasis. Centers may derive new physiologically relevant models that capture the entire metastatic process or develop new experimental and analytical technologies or probes for tracking and monitoring the in vivo dynamics of metastatic cell states.

Honoring the legacy of Paul A. Marks, MD, President Emeritus of Memorial Sloan-Kettering Cancer Center and a distinguished scientist, the Paul Marks Prize for Cancer Research recognizes outstanding young investigators who have made significant contributions to increase the understanding of cancer or improve the treatment of the disease through basic or clinical research. The Paul Marks Prize is awarded every other year to up to three investigators. The first recipients were named in 2001. The winners will present their work at a scientific symposium at Memorial Sloan-Kettering Cancer Center and share a cash award of $150,000. Nominations are now being accepted for the 2013 Paul Marks Prize for Cancer Research. Nominees must be age 45 or younger on the date of the submission deadline, April 30, 2013. Prize winners will be announced in Fall 2013.